Boston Scientific Seeks To Have $324 Mil. J&J Stent Patent Award Set Aside
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific says it may appeal a $324.4 mil. Johnson & Johnson stent patent suit damages award if it is unable to persuade the court to set aside the infringement verdict, arguing that the relevant patents were improperly obtained and are therefore unenforceable.
You may also be interested in...
J&J Patent Infringement Suit Aims To Slow Down Boston Scientific Express
Johnson & Johnson's decision to aggressively defend a 15-year-old stent patent against Boston Scientific represents a low-risk/high-reward strategy for J&J in the emerging drug-eluting stent market
J&J Patent Infringement Suit Aims To Slow Down Boston Scientific Express
Johnson & Johnson's decision to aggressively defend a 15-year-old stent patent against Boston Scientific represents a low-risk/high-reward strategy for J&J in the emerging drug-eluting stent market
J&J v. Boston Scientific
Stent patent infringement award of $324.4 mil. to Johnson & Johnson is set aside and a new damages trial has been ordered in Wilmington federal court, Boston Scientific announces March 28. However, the court upheld a portion of a December 2000 jury verdict that found the NIR stent, made by Medinol for Boston Scientific, infringed one claim of J&J's '762 Palmaz balloon expandable stent patent (1"The Gray Sheet" Dec. 18, 2000, p. 16). "Regardless of the outcome of the new damages trial, we plan on appealing any infringement judgment entered," Boston Scientific says...